Details for Patent: 10,420,734
✉ Email this page to a colleague
Which drugs does patent 10,420,734 protect, and when does it expire?
Patent 10,420,734 protects ORSERDU and is included in one NDA.
This patent has nineteen patent family members in fifteen countries.
Summary for Patent: 10,420,734
Title: | Method of treating cancer using selective estrogen receptor modulators |
Abstract: | Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM. |
Inventor(s): | Wardell Suzanne E., Nelson Erik R., McDonnell Donald P. |
Assignee: | Duke University |
Application Number: | US15129197 |
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 10,420,734
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF AN ER-POSITIVE BREAST CANCER FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY | ⤷ Sign Up | ||||
Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-002 | Jan 27, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF AN ER-POSITIVE BREAST CANCER FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,420,734
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
European Patent Office | 3122426 | ⤷ Sign Up | CA 2024 00007 | Denmark | ⤷ Sign Up |
European Patent Office | 3122426 | ⤷ Sign Up | 2024C/505 | Belgium | ⤷ Sign Up |
European Patent Office | 3122426 | ⤷ Sign Up | 301263 | Netherlands | ⤷ Sign Up |
European Patent Office | 3122426 | ⤷ Sign Up | LUC00331 | Luxembourg | ⤷ Sign Up |
European Patent Office | 3122426 | ⤷ Sign Up | PA2024504 | Lithuania | ⤷ Sign Up |
European Patent Office | 3122426 | ⤷ Sign Up | 122024000013 | Germany | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |